300636 同和药业
未开盘 08-26 09:30:00
资讯
新帖
简况
股市必读：同和药业新发布《关于公司原料药获得FDA注册批准函的公告》
证券之星 · 08-12
股市必读：同和药业新发布《关于公司原料药获得FDA注册批准函的公告》
同和药业(300636.SZ)：米拉贝隆原料药获得FDA注册批准函DA注册批准函
智通财经 · 08-11
同和药业(300636.SZ)：米拉贝隆原料药获得FDA注册批准函DA注册批准函
股市必读：同和药业新发布《关于公司获得澳大利亚药品GMP符合性证书的公告》
证券之星 · 08-05
股市必读：同和药业新发布《关于公司获得澳大利亚药品GMP符合性证书的公告》
同和药业(300636.SZ)：米拉贝隆、恩格列净获得澳大利亚药品GMP符合性证书
智通财经 · 08-04
同和药业(300636.SZ)：米拉贝隆、恩格列净获得澳大利亚药品GMP符合性证书
同和药业（300636）披露通过药品GMP符合性检查公告，7月27日股价上涨2.8%
证券之星 · 07-27
同和药业（300636）披露通过药品GMP符合性检查公告，7月27日股价上涨2.8%
7月1日同和药业涨5.02%，同泰远见混合A基金重仓该股
证券之星 · 07-01
7月1日同和药业涨5.02%，同泰远见混合A基金重仓该股
6月26日同和药业跌5.26%，同泰远见混合A基金重仓该股
证券之星 · 06-26
6月26日同和药业跌5.26%，同泰远见混合A基金重仓该股
6月23日同和药业涨7.82%，同泰远见混合A基金重仓该股
证券之星 · 06-23
6月23日同和药业涨7.82%，同泰远见混合A基金重仓该股
股市必读：同和药业（300636）6月16日董秘有最新回复
证券之星 · 06-17
股市必读：同和药业（300636）6月16日董秘有最新回复
同和药业(300636.SZ)：“罗沙司他”原料药通过CDE审批
智通财经 · 06-16
同和药业(300636.SZ)：“罗沙司他”原料药通过CDE审批
同和药业（300636）披露塞来昔布原料药通过CDE审批公告，6月1日股价上涨2.18%
证券之星 · 06-01
同和药业（300636）披露塞来昔布原料药通过CDE审批公告，6月1日股价上涨2.18%
同和药业(300636.SZ)：“塞来昔布”原料药通过CDE审批
智通财经 · 06-01
同和药业(300636.SZ)：“塞来昔布”原料药通过CDE审批
同和药业（300636）披露2025年年度权益分派实施公告，5月26日股价下跌1.41%
证券之星 · 05-26
同和药业（300636）披露2025年年度权益分派实施公告，5月26日股价下跌1.41%
同和药业（300636）披露获得恩格列净片《药品注册证书》，5月19日股价上涨0.55%
证券之星 · 05-19
同和药业（300636）披露获得恩格列净片《药品注册证书》，5月19日股价上涨0.55%
同和药业(300636.SZ)恩格列净片获得药品注册证书
智通财经 · 05-18
同和药业(300636.SZ)恩格列净片获得药品注册证书
同和药业（300636）披露向特定对象发行股票持续督导保荐总结报告书，5月15日股价下跌1.6%
证券之星 · 05-15
同和药业（300636）披露向特定对象发行股票持续督导保荐总结报告书，5月15日股价下跌1.6%
同和药业宣布美国FDA对其医药产品发出DMF首封充分信函
美股速递 · 05-14
同和药业宣布美国FDA对其医药产品发出DMF首封充分信函
同和药业(300636.SZ)：原料药卡格列净获得美国FDA注册批准函
智通财经 · 05-14
同和药业(300636.SZ)：原料药卡格列净获得美国FDA注册批准函
同和药业（300636）披露将举行2025年度网上业绩说明会，5月08日股价上涨1.95%
证券之星 · 05-08
同和药业（300636）披露将举行2025年度网上业绩说明会，5月08日股价上涨1.95%
【机构调研记录】中加基金调研同和药业、章源钨业等3只个股（附名单）
证券之星 · 05-01
【机构调研记录】中加基金调研同和药业、章源钨业等3只个股（附名单）
加载更多
公司概况
公司名称：
江西同和药业股份有限公司
所属行业：
医药制造业
上市日期：
2017-03-31
主营业务：
江西同和药业股份有限公司的主营业务是化学原料药和医药中间体的研发、生产和销售。公司的主要产品是特色化学原料药及中间体、专利原料药及中间体。公司获批设立了“江西省特色原料药工程中心”、“江西省企业技术中心”、“博士后科研实践基地”、“博士后科研工作站”、“江西省小分子药物合成产业技术工程化中心”、“江西省新药研发产教融合创新中心”等科研中心，2023年继续被认定为“高新技术企业”。
发行价格：
14.47
{"stockData":{"symbol":"300636","market":"SZ","secType":"STK","nameCN":"同和药业","latestPrice":6.96,"timestamp":1787706480000,"preClose":6.96,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":367000000,"shares":420000000,"eps":0.1693,"marketStatus":"未开盘","change":0,"latestTime":"08-26 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.1693,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787707800000},"marketStatusCode":0,"adr":0,"adjPreClose":6.96,"symbolType":"stock","openAndCloseTimeList":[[1787707800000,1787715000000],[1787720400000,1787727600000]],"highLimit":7.66,"lowLimit":6.26,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":419951495,"isCdr":false,"pbRate":1.23,"roa":"--","peRate":41.110455,"roe":"1.03%","epsLYR":0.174,"committee":0,"marketValue":2923000000,"turnoverRate":0,"status":2,"floatMarketCap":2556000000},"requestUrl":"/m/hq/s/300636","defaultTab":"news","newsList":[{"id":"2658917634","title":"股市必读：同和药业新发布《关于公司原料药获得FDA注册批准函的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658917634","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658917634?lang=zh_cn&edition=full","pubTime":"2026-08-12 02:08","pubTimestamp":1786471694,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，同和药业报收于7.03元，下跌0.28%，换手率1.53%，成交量5.62万手，成交额3961.46万元。公司公告汇总关于公司原料药获得FDA注册批准函的公告江西同和药业股份有限公司近日收到美国食品药品监督管理局签发的米拉贝隆原料药注册批准函DMF No Further Comments Letter。该药品为选择性β3－肾上腺受体激动剂，用于治疗膀胱过度活动症。FDA已完成对公司米拉贝隆原料药DMF文件的技术审评，可满足关联制剂客户ANDA申报要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200002062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658995180","title":"同和药业(300636.SZ)：米拉贝隆原料药获得FDA注册批准函DA注册批准函","url":"https://stock-news.laohu8.com/highlight/detail?id=2658995180","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658995180?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:59","pubTimestamp":1786438775,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)发布公告，公司于近日收到美国食品药品监督管理局(以下简称“FDA”)签发的米拉贝隆原料药注册批准函 DMF No Further Comments Letter(以下简称“NFC Letter”)。米拉贝隆是一种选择性β3-肾上腺受体激动剂，可通过激活膀胱逼尿肌上的β3-肾上腺受体而提高膀胱充盈和贮尿能力，临床用于治疗急迫性尿失禁、尿急、尿频等症状的膀胱过度活动症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","300636","BK4588","BK4585","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657729563","title":"股市必读：同和药业新发布《关于公司获得澳大利亚药品GMP符合性证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657729563","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657729563?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:20","pubTimestamp":1785867622,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，同和药业报收于6.85元，上涨0.15%，换手率1.81%，成交量6.63万手，成交额4573.48万元。当日关注点交易信息汇总：8月4日主力资金净流出295.83万元，占总成交额6.47%。公司公告汇总关于公司获得澳大利亚药品GMP符合性证书的公告江西同和药业股份有限公司近日收到澳大利亚药品管理局颁发的米拉贝隆、恩格列净原料药GMP符合性证书，认证范围为原料药米拉贝隆和恩格列净，有效期至2028年8月3日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656536715","title":"同和药业(300636.SZ)：米拉贝隆、恩格列净获得澳大利亚药品GMP符合性证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2656536715","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656536715?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:51","pubTimestamp":1785833461,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)发布公告，公司于近日收到澳大利亚药品管理局(TGA)颁发的米拉贝隆、恩格列净药品GMP符合性证书。米拉贝隆是一种选择性β3-肾上腺受体激动剂，可通过激活膀胱逼尿肌上的β3-肾上腺受体而提高膀胱充盈和贮尿能力，临床用于治疗急迫性尿失禁、尿急、尿频等症状的膀胱过度活动症。恩格列净适用于治疗2型糖尿病。公司此次首次通过TGA的GMP认证，表明公司在质量体系和生产环境设施等方面得到TGA的认可，澳大利亚是国际药品认证合作组织(PIC/S)的成员国，这一认证有利于公司继续推动国际市场的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654046912","title":"同和药业（300636）披露通过药品GMP符合性检查公告，7月27日股价上涨2.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654046912","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654046912?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:34","pubTimestamp":1785162858,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘，同和药业报收于6.6元，较前一交易日上涨2.8%，最新总市值为27.72亿元。同日，公司披露《关于公司通过药品GMP符合性检查的公告》。公告显示，江西同和药业股份有限公司收到江西省药品监督管理局的药品GMP符合性检查告知书，公司原料药美阿沙坦钾和甲苯磺酸艾多沙班通过GMP符合性检查。此次通过检查有利于公司拓展产品在国内市场的销售，形成国内外市场同步销售格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700035059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516281","title":"7月1日同和药业涨5.02%，同泰远见混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648516281?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:53","pubTimestamp":1782896005,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日同和药业涨5.02%，收盘报6.69元，换手率1.91%，成交量7.02万手，成交额4612.5万元。重仓同和药业的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为同泰基金的同泰远见混合A。同泰远见混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646358919","title":"6月26日同和药业跌5.26%，同泰远见混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646358919","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646358919?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:58","pubTimestamp":1782464327,"startTime":"0","endTime":"0","summary":"证券之星消息，6月26日同和药业跌5.26%，收盘报6.3元，换手率2.25%，成交量8.27万手，成交额5296.81万元。重仓同和药业的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为同泰基金的同泰远见混合A。同泰远见混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600030809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645688148","title":"6月23日同和药业涨7.82%，同泰远见混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645688148","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645688148?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:40","pubTimestamp":1782204015,"startTime":"0","endTime":"0","summary":"证券之星消息，6月23日同和药业涨7.82%，收盘报7.03元，换手率4.48%，成交量16.44万手，成交额1.14亿元。重仓同和药业的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为同泰基金的同泰远见混合A。同泰远见混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644798318","title":"股市必读：同和药业（300636）6月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644798318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644798318?lang=zh_cn&edition=full","pubTime":"2026-06-17 04:44","pubTimestamp":1781642651,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，同和药业报收于6.61元，下跌0.9%，换手率1.31%，成交量4.8万手，成交额3148.19万元。公司公告汇总关于公司原料药通过CDE审批的公告江西同和药业股份有限公司近日获悉，公司提交的“罗沙司他”原料药通过国家药品监督管理局药品审评中心审批，登记号为Y20240001574，审评审批结果为A，已批准在上市制剂中使用。该原料药用于治疗慢性肾脏病引起的贫血。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700003844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643730440","title":"同和药业(300636.SZ)：“罗沙司他”原料药通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2643730440","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643730440?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:04","pubTimestamp":1781600658,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)发布公告，公司近日从国家药品监督管理局药品审评中心(CDE)“原辅包登记信息公示”平台查询获悉，公司提交的“罗沙司他”原料药通过了CDE审批。罗沙司他主要用于治疗慢性肾脏病(CKD)引起的贫血(包括透析及非透析患者)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4017","CDE","LU1223083913.SGD","LU1223082519.USD","BK0239","300636","LU1223082196.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640958046","title":"同和药业（300636）披露塞来昔布原料药通过CDE审批公告，6月1日股价上涨2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640958046","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640958046?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:16","pubTimestamp":1780308996,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，同和药业报收于7.03元，较前一交易日上涨2.18%，最新总市值为29.52亿元。同日，公司发布《关于公司原料药通过CDE审批的公告》。公告显示，江西同和药业股份有限公司近日获悉，公司提交的“塞来昔布”原料药通过国家药品监督管理局药品审评中心审批，登记号为Y20240001113，审评审批结果为A，已批准在上市制剂中使用。塞来昔布主要用于缓解骨关节炎、成人类风湿关节炎、强直性脊柱炎的症状和体征，以及治疗成人急性疼痛。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100029684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640931032","title":"同和药业(300636.SZ)：“塞来昔布”原料药通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2640931032","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640931032?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:00","pubTimestamp":1780300839,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)发布公告，公司近日从国家药品监督管理局药品审评中心(CDE)“原辅包登记信息公示”平台查询获悉，公司提交的“塞来昔布”原料药通过了CDE审批。塞来昔布主要用于缓解骨关节炎、成人类风湿关节炎、强直性脊柱炎的症状和体征，以及用于治疗成人急性疼痛。公司“塞来昔布”原料药通过CDE审批，表明该原料药符合中国相关药品审评技术标准，已批准在国内上市制剂中使用，有利于公司拓展产品在国内市场的销售，形成国内国外市场同步销售的良好格局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223082519.USD","BK0239","CDE","BK4017","LU1223082196.USD","LU1223083913.SGD","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638543765","title":"同和药业（300636）披露2025年年度权益分派实施公告，5月26日股价下跌1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638543765","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638543765?lang=zh_cn&edition=full","pubTime":"2026-05-26 22:47","pubTimestamp":1779806835,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘，同和药业报收于7.01元，较前一交易日下跌1.41%，最新总市值为29.44亿元。该股当日开盘7.09元，最高7.09元，最低6.94元，成交额达3719.51万元，换手率为1.45%。同日，公司发布《2025年年度权益分派实施公告》。公告显示，江西同和药业股份有限公司于2026年5月19日召开2025年年度股东会，审议通过《关于<公司2025年度利润分配预案>的议案》。本次权益分派股权登记日为2026年6月2日，除权除息日为2026年6月3日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600041499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636837161","title":"同和药业（300636）披露获得恩格列净片《药品注册证书》，5月19日股价上涨0.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636837161","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636837161?lang=zh_cn&edition=full","pubTime":"2026-05-19 18:12","pubTimestamp":1779185541,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘，同和药业报收于7.32元，较前一交易日上涨0.55%，最新总市值为30.74亿元。江西同和药业股份有限公司近日收到国家药品监督管理局核准签发的恩格列净片《药品注册证书》，规格为10mg、25mg，注册分类为化学药品4类，上市许可持有人为公司本身。目前国内已有41家企业获得该药品注册证书。2024年该药品在二级及以上公立医疗机构销售额约9.73亿元，2025年前三季度销售额约7.47亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900035031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636831020","title":"同和药业(300636.SZ)恩格列净片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2636831020","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636831020?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:01","pubTimestamp":1779102105,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业 发布公告，公司近日收到国家药品监督管理局核准签发的恩格列净片的《药品注册证书》。据悉，恩格列净片适用于治疗2型糖尿病。根据药渡数据库数据显示，2024年恩格列净片在我国二级及以上公立医疗机构销售额约为9.73亿元，2025年第一至第三季度销售额约为7.47亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"同和药业(300636.SZ)恩格列净片获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635083942","title":"同和药业（300636）披露向特定对象发行股票持续督导保荐总结报告书，5月15日股价下跌1.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635083942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635083942?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:18","pubTimestamp":1778840301,"startTime":"0","endTime":"0","summary":"近日，同和药业披露《招商证券股份有限公司关于江西同和药业股份有限公司向特定对象发行股票持续督导保荐总结报告书》。公告显示，招商证券作为该公司向特定对象发行股票的保荐机构，持续督导期已于2025年12月31日届满。持续督导期间，保荐机构按规定开展尽职调查、文件申报、信息披露审阅、募集资金使用监督等工作，未发现重大违规事项。公司募集资金尚未使用完毕，保荐机构将在督导期结束后继续对募集资金存放与使用进行专项督导。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500035378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169739277","title":"同和药业宣布美国FDA对其医药产品发出DMF首封充分信函","url":"https://stock-news.laohu8.com/highlight/detail?id=1169739277","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169739277?lang=zh_cn&edition=full","pubTime":"2026-05-14 12:02","pubTimestamp":1778731336,"startTime":"0","endTime":"0","summary":"同和药业宣布，美国食品药品监督管理局已对其旗下的一款医药产品发出药物主文件首封充分信函。这一进展标志着该产品在监管审查流程中迈出了关键一步，为公司后续的市场拓展计划奠定了重要的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635769079","title":"同和药业(300636.SZ)：原料药卡格列净获得美国FDA注册批准函","url":"https://stock-news.laohu8.com/highlight/detail?id=2635769079","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635769079?lang=zh_cn&edition=full","pubTime":"2026-05-14 11:49","pubTimestamp":1778730580,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业 发布公告，公司于近日收到美国食品药品监督管理局签发的卡格列净原料药注册批准函DMF First Adequate Letter。卡格列净产品获得美国FDA签发的 FA Letter，表明 FDA 已完成对公司卡格列净原料药 DMF 文件的技术审评，可满足关联制剂客户的 ANDA 申报要求。卡格列净原料药此次通过技术审评，有利于公司拓展市场、开拓客户，将对公司进一步扩大国际市场业务起到积极作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300636","LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633431273","title":"同和药业（300636）披露将举行2025年度网上业绩说明会，5月08日股价上涨1.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633431273","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633431273?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:51","pubTimestamp":1778233909,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，同和药业报收于7.84元，较前一交易日上涨1.95%，最新总市值为32.92亿元。同和药业近日发布《关于举行2025年度网上业绩说明会的公告》。公告显示，公司已于2026年4月29日在巨潮资讯网披露《2025年年度报告》，并将于2026年5月13日下午15:00-16:00通过深圳证券交易所“互动易”平台举行2025年度网上业绩说明会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800032200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632693558","title":"【机构调研记录】中加基金调研同和药业、章源钨业等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2632693558","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632693558?lang=zh_cn&edition=full","pubTime":"2026-05-01 08:01","pubTimestamp":1777593703,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月30日披露的机构调研信息，中加基金近期对3家上市公司进行了调研，相关名单如下：1）同和药业 调研纪要：2025年新产品收入同比增长近15%，销售收入占比达50.05%，首次超过老产品；2026年一季度同比增长23.64%，占比达54.07%。2）章源钨业 调研纪要：2025年，公司营业收入520,194.40万元，较上年同期增长41.62%；归属于上市公司股东的净利润29,042.56万元，较上年同期增长68.82%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050100008104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","002378","BK0233","300636","BK0182"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787706492008,"stockEarnings":[{"period":"1week","weight":-0.0252},{"period":"1month","weight":0.0841},{"period":"3month","weight":0.0132},{"period":"6month","weight":-0.1686},{"period":"1year","weight":-0.1734},{"period":"ytd","weight":-0.0678}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":0.0197},{"period":"3month","weight":-0.0499},{"period":"6month","weight":-0.062},{"period":"1year","weight":0.0015},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江西同和药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13085人(较上一季度减少18.34%)","perCapita":"28071股","listingDate":"2017-03-31","address":"江西省宜春市奉新县江西奉新高新技术产业园区","registeredCapital":"41995万元","survey":" 江西同和药业股份有限公司的主营业务是化学原料药和医药中间体的研发、生产和销售。公司的主要产品是特色化学原料药及中间体、专利原料药及中间体。公司获批设立了“江西省特色原料药工程中心”、“江西省企业技术中心”、“博士后科研实践基地”、“博士后科研工作站”、“江西省小分子药物合成产业技术工程化中心”、“江西省新药研发产教融合创新中心”等科研中心，2023年继续被认定为“高新技术企业”。","listedPrice":14.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同和药业,300636,同和药业股票,同和药业股票老虎,同和药业股票老虎国际,同和药业行情,同和药业股票行情,同和药业股价,同和药业股市,同和药业股票价格,同和药业股票交易,同和药业股票购买,同和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}